{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(32)"],"submitter":["Swami U"],"funding":["Astellas Pharma"],"pubmed_abstract":["<b>Aim:</b> Androgen receptor pathway inhibitors (ARPIs) prolong metastasis-free survival and overall survival in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). This study aimed to evaluate real-world treatment patterns, utilization and survival outcomes in patients with nmCRPC.<b>Patients & methods:</b> This retrospective cohort study used Optum database electronic health records of patients with nmCRPC from 1 January 2007 to 31 December 2020 in the US.<b>Results:</b> Of 1955 patients, >80% received androgen-deprivation therapy (ADT) alone or ADT + first-generation nonsteroidal antiandrogen (NSAA) as first-line treatment, while only 8.24% received ADT + ARPI. ADT + ARPI remained underutilized even among those with high-risk nmCRPC. Further, ADT + NSAA had no survival benefit compared with ADT alone.<b>Conclusion:</b> Practice-improvement strategies are needed for treatment intensification with ARPIs for patients with nmCRPC."],"journal":["Future oncology (London, England)"],"pagination":["2467-2480"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11520573"],"repository":["biostudies-literature"],"pubmed_title":["Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States."],"pmcid":["PMC11520573"],"pubmed_authors":["Ramaswamy K","Swami U","Bunner SH","Young C","Gupta S","Chastek B","Diessner B","El Chaar N","Hong A","Xie B"],"additional_accession":[]},"is_claimable":false,"name":"Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States.","description":"<b>Aim:</b> Androgen receptor pathway inhibitors (ARPIs) prolong metastasis-free survival and overall survival in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). This study aimed to evaluate real-world treatment patterns, utilization and survival outcomes in patients with nmCRPC.<b>Patients & methods:</b> This retrospective cohort study used Optum database electronic health records of patients with nmCRPC from 1 January 2007 to 31 December 2020 in the US.<b>Results:</b> Of 1955 patients, >80% received androgen-deprivation therapy (ADT) alone or ADT + first-generation nonsteroidal antiandrogen (NSAA) as first-line treatment, while only 8.24% received ADT + ARPI. ADT + ARPI remained underutilized even among those with high-risk nmCRPC. Further, ADT + NSAA had no survival benefit compared with ADT alone.<b>Conclusion:</b> Practice-improvement strategies are needed for treatment intensification with ARPIs for patients with nmCRPC.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2025-04-04T13:19:46.29Z","creation":"2025-04-04T13:19:46.29Z"},"accession":"S-EPMC11520573","cross_references":{"pubmed":["39073610"],"doi":["10.1080/14796694.2024.2373681"]}}